Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297128 | 0.87 | ACE2 (0.36) | ACE2BRD4CCR8KMT2AP2RX7 | |
| SCHEMBL18999654 | 0.81 | CCR8 (0.33) | ACE2BRD4CCR8KMT2AP2RX7 | |
| SCHEMBL19007000 | 0.78 | — | — | |
| SCHEMBL23798400 | 0.76 | P2RX7 (0.37) | ACE2P2RX7 | |
| SCHEMBL27271494 | 0.76 | TSHR (0.34) | ACE2P2RX7BRD9 | |
| SCHEMBL20350275 | 0.76 | DAO (0.30) | — | |
| SCHEMBL20756906 | 0.76 | HTR2A (0.39) | CCR8KMT2AP2RX7 | |
| SCHEMBL25091485 | 0.76 | GPR55 (0.35) | CCR8 | |
| SCHEMBL13184313 | 0.74 | AHR (0.38) | CCR8KMT2AP2RX7 | |
| SCHEMBL2382172 | 0.74 | AHR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | ACE2 2866/4885BRD4 17/4885CCR8 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.